[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@JamesEKrause Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1091405261741404162.png) @JamesEKrause Biotech Jim

Biotech Jim posts on X about $crvs, $idya, $acrs, hosting the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1091405261741404162/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXX +99%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +57%

### Mentions: X [#](/creator/twitter::1091405261741404162/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:posts_active.svg)

- X Week XX +50%
- X Month XX +6.10%
- X Months XXX -XX%
- X Year XXX +177%

### Followers: XXXXXX [#](/creator/twitter::1091405261741404162/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:followers.svg)

- X Week XXXXXX +0.19%
- X Month XXXXXX +1.80%
- X Months XXXXXX +8.50%
- X Year XXXXXX +18%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1091405261741404162/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1091405261741404162/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1091405261741404162/influence)
---

**Social category influence**
[finance](/list/finance)  XXX%

**Social topic influence**
[$crvs](/topic/$crvs) #8, [$idya](/topic/$idya) 8.7%, [$acrs](/topic/$acrs) 4.35%, [hosting](/topic/hosting) 4.35%, [$mdgl](/topic/$mdgl) 4.35%, [$mash](/topic/$mash) 4.35%, [cnbc](/topic/cnbc) 4.35%, [targets](/topic/targets) 4.35%, [$imrx](/topic/$imrx) 4.35%, [$23b](/topic/$23b) XXXX%

**Top accounts mentioned or mentioned by**
[@playertwoq](/creator/undefined) [@seedy19tron](/creator/undefined) [@snupsnus](/creator/undefined) [@dudebiotech](/creator/undefined) [@wallstsai](/creator/undefined) [@cashinsider](/creator/undefined) [@badinvestor99](/creator/undefined) [@andre_agtc](/creator/undefined)

**Top assets mentioned**
[IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Axcelis Technologies Inc (ACLS)](/topic/$acls)
### Top Social Posts [#](/creator/twitter::1091405261741404162/posts)
---
Top posts by engagements in the last XX hours

"On the ITK enzyme and its inhibition for TH2 inflammatory diseases. I will be listening in on the Aclarus presentations today: Aclaris Therapeutics to Host In-Person and Webcast R&D Day Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets in New York on October XX 2025 $ACRS $CRVS"  
[X Link](https://x.com/JamesEKrause/status/1978082130614698409) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-14T12:55Z 13.2K followers, 8772 engagements


"$CRVS is starting to get recognized"  
[X Link](https://x.com/JamesEKrause/status/1978536636733391182) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-15T19:01Z 13.2K followers, 10.1K engagements


"Madrigal's CEO Bill Seybold discusses the $MDGL $MASH market and sales on CNBC"  
[X Link](https://x.com/JamesEKrause/status/1978953279380787610) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-16T22:36Z 13.2K followers, 3890 engagements


"My comments for the circular file fwiw. $CRVS is my fav nascent up and coming biotech for several reasons. X. Innovation (early) on this target ITK inhibition with a compelling pleiotropic response X. Initial clinical target Peripheral T-cell Lymphoma (PTCL) with dramatic unmet medical need X. Large targeted inflammation markets with Atopic Dermatitis in the current cross hairs ( $REGN has a blockbuster here with the injectable mAb #dupixent targeting the IL-4R that then limits the production of both Il-4 and Il-13 pro-inflammatory cytokines X. Skilled CEO Richard Miller MD a #lymphoma doc"  
[X Link](https://x.com/JamesEKrause/status/1957093827875045565) [@JamesEKrause](/creator/x/JamesEKrause) 2025-08-17T14:55Z 13.2K followers, 10.9K engagements


"A $CRVS ITK degrader program would definitely be of interest. I would assume significant ongoing competition"  
[X Link](https://x.com/JamesEKrause/status/1970833458353304044) [@JamesEKrause](/creator/x/JamesEKrause) 2025-09-24T12:51Z 13.2K followers, 4286 engagements


"$IMRX Company PR on pancreatic patient data update with Tebimetinib + MGNP note on stock offering and a Reuters News Brief. Sept XX (Reuters) 5:21 PM ET Immuneering Corp * IMMUNEERING ANNOUNCES EXTRAORDINARY XX% OVERALL SURVIVAL AT X MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP * IMMUNEERING CORP(IMRX) - ATEBIMETINIB + MGNP SHOWS XX% PFS AT X MONTHS IN PANCREATIC CANCER * IMMUNEERING CORP(IMRX) - EXPECTS REGULATORY FEEDBACK ON PIVOTAL TRIAL PLANS IN Q4 2025 * IMMUNEERING CORP(IMRX) - TO INITIATE PIVOTAL TRIAL BY END OF 2025"  
[X Link](https://x.com/JamesEKrause/status/1971000627325988965) [@JamesEKrause](/creator/x/JamesEKrause) 2025-09-24T23:55Z 13.2K followers, 6955 engagements


"Performing some DD on $IDYA IDEAYA Biosciences trying to get a synopsis of their many biopharma collaborations. New to this name fwiw. Some friends of mine on X believe this company may be a buyout candidate. Current mkt cap $2.3B with some uncertainty of # of fully diluted shares (stock option grants etc). As usual please feel free to provide commentary (+ and -) on this interesting company/business plan. Partnered Programs and Collaborative Details via Grok my consultant. IDEAYA Biosciences has established multiple strategic partnerships to advance its precision oncology pipeline focusing"  
[X Link](https://x.com/JamesEKrause/status/1977085929811583266) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-11T18:56Z 13.2K followers, 16.7K engagements


"Regarding the accurate spelling of Aclaris $ACLS. Disclosure: I picked up some share ystdy for the 2026 ews flow. Never really followed the company before as they are friends with the 'bad luck bears'. Their approaches today are reasonable but 2026 is do or die. Activist investors such as Kevin T may have helped buoy the ship but it is all about the next yr company trial readouts. For the #ITK inhibitor with more acute selectivity (IND in 2026) this may be too little too late if the clintrials do not pan out. I invested since I like the risk reward but I sure would like to know the FDA regs"  
[X Link](https://x.com/JamesEKrause/status/1978577493327331655) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-15T21:43Z 13.2K followers, 1382 engagements


"Grok for the purposes of continuing due diligence tell me about the business plan pipeline most valuable asset the management and investors in Ideaya Biosciences $IDYA"  
[X Link](https://x.com/JamesEKrause/status/1979549315434770694) [@JamesEKrause](/creator/x/JamesEKrause) 2025-10-18T14:05Z 13.2K followers, 1891 engagements